Role of the TPX2/NCOA5 axis in regulating proliferation, migration, invasion and angiogenesis of breast cancer cells

Wang,Tian; Zhang,Fulin; Zhang,Peirong

doi:10.3892/etm.2023.12003

Role of the TPX2/NCOA5 axis in regulating proliferation, migration, invasion and angiogenesis of breast cancer cells

Authors:
- Tian Wang
- Fulin Zhang
- Peirong Zhang
View Affiliations

Affiliations: Department of Oncology Hematology, Yan'an People's Hospital, Yan'an, Shaanxi 716000, P.R. China, Department of Pathology, Yantian District People's Hospital, Shenzhen, Guangdong 518000, P.R. China
Published online on: May 9, 2023 https://doi.org/10.3892/etm.2023.12003
Article Number: 304
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is a common malignant tumor in women. Increasing evidence has demonstrated that nuclear receptor coactivator 5 (NCOA5) and targeting protein for xenopus kinesin‑like protein 2 (TPX2) serve vital roles in the progression of breast cancer. However, to the best of our knowledge, the molecular mechanisms underlying the involvement of TPX2/NCOA5 in the development of breast cancer are not fully understood at present. In the present study, the expression levels of NCOA5 and TPX2 were compared between paired non‑tumor and tumor tissues of patients with breast cancer using the TNMplot tool. Expression differences of NCOA5 and TPX2 in human breast epithelial cell lines (MCF10A and MCF12A) and human breast cancer cell lines (MCF7 and T47D) were assessed via reverse transcription‑quantitative PCR and western blotting. Additionally, proliferation, migration and invasion of breast cancer cells were determined via Cell Counting Kit‑8, would healing and transwell assays. In vitro angiogenesis was determined using a tube formation assay. Furthermore, TPX2 was identified as a high‑confidence NCOA5 interactor based on BioPlex network data sets. A co‑immunoprecipitation assay was adopted to confirm the interaction between TPX2 and NCOA5. The present study revealed that TPX2 and NCOA5 were highly expressed in breast cancer cells. TPX2 interacted with NCOA5 and there was a positive association between TPX2 and NCOA5 expression. NOCA5 knockdown repressed the proliferation, migration, invasion and in vitro angiogenesis of breast cancer cells. In addition, TPX2 knockdown suppressed the proliferation, migration and invasion of breast cancer cells, and inhibited in vitro angiogenesis, and all of these effects were reversed following NCOA5 overexpression. In conclusion, NCOA5 was a downstream target of TPX2 in enhancing proliferation, migration, invasion and angiogenesis of breast cancer cells.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar
2	DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A and Siegel RL: Breast cancer statistics, 2019. CA Cancer J Clin. 69:438–451. 2019.PubMed/NCBI View Article : Google Scholar
3	Henriques B, Mendes F and Martins D: Immunotherapy in breast cancer: When, how, and what challenges. Biomedicines. 9(1687)2021.PubMed/NCBI View Article : Google Scholar
4	Liang Y, Zhang H, Song X and Yang Q: Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 60:14–27. 2020.PubMed/NCBI View Article : Google Scholar
5	Chen GQ, Tian H, Yue WM, Li L, Li SH, Qi L, Gao C, Si LB and Lu M: NCOA5 low expression correlates with survival in esophageal squamous cell carcinoma. Med Oncol. 31(376)2014.PubMed/NCBI View Article : Google Scholar
6	Sun K, Wang S, He J, Xie Y, He Y, Wang Z and Qin L: NCOA5 promotes proliferation, migration and invasion of colorectal cancer cells via activation of PI3K/AKT pathway. Oncotarget. 8:107932–107946. 2017.PubMed/NCBI View Article : Google Scholar
7	He J, Zhang W, Li A, Chen F and Luo R: Knockout of NCOA5 impairs proliferation and migration of hepatocellular carcinoma cells by suppressing epithelial-to-mesenchymal transition. Biochem Biophys Res Commun. 500:177–183. 2018.PubMed/NCBI View Article : Google Scholar
8	Ye XH, Huang DP and Luo RC: NCOA5 is correlated with progression and prognosis in luminal breast cancer. Biochem Biophys Res Commun. 482:253–256. 2017.PubMed/NCBI View Article : Google Scholar
9	Xia E, Hu W, Bhandari A, Sindan N and Huang D: Nuclear receptor coactivator 5 is correlated with progression in breast carcinoma. Anticancer Agents Med Chem. 21:2520–2524. 2021.PubMed/NCBI View Article : Google Scholar
10	Safari MS, King MR, Brangwynne CP and Petry S: Interaction of spindle assembly factor TPX2 with importins-α/β inhibits protein phase separation. J Biol Chem. 297(100998)2021.PubMed/NCBI View Article : Google Scholar
11	Gomes-Filho SM, Dos Santos EO, Bertoldi ERM, Scalabrini LC, Heidrich V, Dazzani B, Levantini E, Reis EM and Bassères DS: Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer. Cell Oncol (Dordr). 43:445–460. 2020.PubMed/NCBI View Article : Google Scholar
12	Zhang B, Zhang M, Li Q, Yang Y, Shang Z and Luo J: TPX2 mediates prostate cancer epithelial-mesenchymal transition through CDK1 regulated phosphorylation of ERK/GSK3β/SNAIL pathway. Biochem Biophys Res Commun. 546:1–6. 2021.PubMed/NCBI View Article : Google Scholar
13	Zhu H, Liu J, Feng J, Zhang Q, Bian T, Li X, Sun H, Zhang J and Liu Y: Overexpression of TPX2 predicts poor clinical outcome and is associated with immune infiltration in hepatic cell cancer. Medicine (Baltimore). 99(e23554)2020.PubMed/NCBI View Article : Google Scholar
14	Yang Y, Li DP, Shen N, Yu XC, Li JB, Song Q and Zhang JH: TPX2 promotes migration and invasion of human breast cancer cells. Asian Pac J Trop Med. 8:1064–1070. 2015.PubMed/NCBI View Article : Google Scholar
15	Jiang Y, Liu Y, Tan X, Yu S and Luo J: TPX2 as a novel prognostic indicator and promising therapeutic target in triple-negative breast cancer. Clin Breast Cancer. 19:450–455. 2019.PubMed/NCBI View Article : Google Scholar
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
17	Kumar S, Srivastav RK, Wilkes DW, Ross T, Kim S, Kowalski J, Chatla S, Zhang Q, Nayak A, Guha M, et al: Estrogen-dependent DLL1-mediated notch signaling promotes luminal breast cancer. Oncogene. 38:2092–2107. 2019.PubMed/NCBI View Article : Google Scholar
18	Zhang Y, Shu C, Maimaiti Y, Wang S, Lu C and Zhou J: LRP6 as a biomarker of poor prognosis of breast cancer. Gland Surg. 10:2414–2427. 2021.PubMed/NCBI View Article : Google Scholar
19	Tan Y, Liu F and Xu P: Knockdown of NCOA5 suppresses viability, migration and epithelial-mesenchymal transition, and induces adhesion of breast cancer cells. Oncol Lett. 22(694)2021.PubMed/NCBI View Article : Google Scholar
20	Chen WZ, Jiang JX, Yu XY, Xia WJ, Yu PX, Wang K, Zhao ZY and Chen ZG: Endothelial cells in colorectal cancer. World J Gastrointest Oncol. 11:946–956. 2019.PubMed/NCBI View Article : Google Scholar
21	Tu J, Fang Y, Han D, Tan X, Jiang H, Gong X, Wang X, Hong W and Wei W: Activation of nuclear factor-κB in the angiogenesis of glioma: Insights into the associated molecular mechanisms and targeted therapies. Cell Prolif. 54(e12929)2021.PubMed/NCBI View Article : Google Scholar
22	Zhang Q, Lu S, Li T, Yu L, Zhang Y, Zeng H, Qian X, Bi J and Lin Y: ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway. J Exp Clin Cancer Res. 38(173)2019.PubMed/NCBI View Article : Google Scholar
23	Cao J, Liu X, Yang Y, Wei B, Li Q, Mao G, He Y, Li Y, Zheng L, Zhang Q, et al: Decylubiquinone suppresses breast cancer growth and metastasis by inhibiting angiogenesis via the ROS/p53/BAI1 signaling pathway. Angiogenesis. 23:325–338. 2020.PubMed/NCBI View Article : Google Scholar
24	Zhou F, Wang M, Aibaidula M, Zhang Z, Aihemaiti A, Aili R, Chen H, Dong S, Wei W and Maimaitiaili A: TPX2 promotes metastasis and serves as a marker of poor prognosis in non-small cell lung cancer. Med Sci Monit. 26(e925147)2020.PubMed/NCBI View Article : Google Scholar